AstraZeneca PLC
AZN
$187.03
-$2.72-1.43%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 60.44B | 58.74B | 58.13B | 56.50B | 54.98B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 60.44B | 58.74B | 58.13B | 56.50B | 54.98B |
| Cost of Revenue | 11.19B | 10.75B | 9.74B | 10.03B | 9.66B |
| Gross Profit | 49.25B | 47.99B | 48.39B | 46.47B | 45.32B |
| SG&A Expenses | 20.53B | 20.13B | 19.28B | 19.37B | 19.45B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -297.00M | -221.00M | -312.00M | -248.00M | -236.00M |
| Total Operating Expenses | 45.64B | 44.57B | 42.34B | 42.27B | 41.49B |
| Operating Income | 14.80B | 14.17B | 15.79B | 14.23B | 13.49B |
| Income Before Tax | 12.91B | 12.40B | 11.44B | 10.02B | 9.29B |
| Income Tax Expenses | 2.52B | 2.17B | 2.04B | 1.72B | 1.51B |
| Earnings from Continuing Operations | 10.39K | 10.23K | 9.40K | 8.30K | 7.78K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -4.00M | -8.00M | -5.00M | -7.00M | -10.00M |
| Net Income | 10.39B | 10.23B | 9.40B | 8.30B | 7.77B |
| EBIT | 14.80B | 14.17B | 15.79B | 14.23B | 13.49B |
| EBITDA | 19.87B | 19.16B | 20.29B | 19.01B | 18.16B |
| EPS Basic | 6.70 | 6.59 | 6.06 | 5.35 | 5.01 |
| Normalized Basic EPS | 5.42 | 5.19 | 5.83 | 5.23 | 4.94 |
| EPS Diluted | 6.64 | 6.54 | 6.02 | 5.31 | 4.97 |
| Normalized Diluted EPS | 5.38 | 5.15 | 5.79 | 5.19 | 4.90 |
| Average Basic Shares Outstanding | 6.20B | 6.20B | 6.20B | 6.20B | 6.20B |
| Average Diluted Shares Outstanding | 6.24B | 6.24B | 6.24B | 6.24B | 6.25B |
| Dividend Per Share | 3.20 | 3.20 | 3.13 | 3.13 | 3.10 |
| Payout Ratio | 47.24% | 48.59% | 52.89% | 59.51% | 63.60% |